About Keratin, type I cuticular Ha4
Keratin, type I cuticular Ha4 (KRT34) is a protein
from Homo sapiens identified by UniProt accession
O76011, 394 residues long.
MolForge cross-references it against 0 known binders and
75 disease associations.
Target properties
| Protein name | Keratin, type I cuticular Ha4 |
| UniProt accession | O76011 |
| Gene | KRT34 |
| Organism | Homo sapiens |
| Length | 394 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (75)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.18
- head and neck squamous cell carcinoma · score 0.18
- breast adenocarcinoma · score 0.18
- esophageal cancer · score 0.14
- low grade glioma · score 0.11
- Hyperlipoproteinemia type 1 · score 0.05
- cryptorchidism · score 0.04
- Testicular regression syndrome · score 0.04
- isolated congenital hypogonadotropic hypogonadism · score 0.04
- familial apolipoprotein C-II deficiency · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O76011-F1 | alphafold | PREDICTED | 79.85 | — |
Amino-acid sequence (394 residues)
MSYSCCLPSL GCRTSCSSRP CVPPSCHGYT LPGACNIPAN VSNCNWFCEG SFNGSEKETM QFLNDRLASY LEKVRQLERD NAELEKLIQE RSQQQEPLLC PSYQSYFKTI EELQQKILCA KAENARLVVN IDNAKLASDD FRSKYQTEQS LRLLVESDIN SIRRILDELT LCKSDLESQV ESLREELICL KKNHEEEVNT LRSQLGDRLN VEVDTAPTVD LNQVLNETRS QYEALVEINR REVEQWFATQ TEELNKQVVS SSEQLQSCQA EIIELRRTVN ALEIELQAQH NLRDSLENTL TESEAHYSSQ LSQVQSLITN VESQLAEIRC DLERQNQEYQ VLLDVRARLE CEINTYRSLL ESEDCKLPCN PCATTNASGN SCGPCGTSQK GCCN
Explore Keratin, type I cuticular Ha4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets